Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00483561
What this trial is testing

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Prostate Cancer
University of Nebraska 26
Testing effectiveness (Phase 2)Study completedNCT00439270
What this trial is testing

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Bristol-Myers Squibb 49
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Testing effectiveness (Phase 2)Study completedNCT00513071
What this trial is testing

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate Cancer
National Cancer Institute (NCI) 28
Not applicableUnknownNCT03658434
What this trial is testing

Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Zealand University Hospital 34
Testing effectiveness (Phase 2)Study completedNCT00291005
What this trial is testing

PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone

Who this might be right for
Prostatic Neoplasms
Sanofi 42
Testing effectiveness (Phase 2)Study completedNCT01338792
What this trial is testing

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-resistant Prostate CancerRecurrent Prostate Cancer
University of Southern California 47
Testing effectiveness (Phase 2)Study completedNCT00708214
What this trial is testing

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 28
Testing effectiveness (Phase 2)Study completedNCT00448409
What this trial is testing

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
The Methodist Hospital Research Institute 27
Early research (Phase 1)Study completedNCT00667537
What this trial is testing

PK in Pts With HRPC & Skeletal Metastes

Who this might be right for
Prostatic Neoplasms
Bayer 6
Testing effectiveness (Phase 2)Study completedNCT02288936
What this trial is testing

Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Spanish Oncology Genito-Urinary Group 98
Not applicableStudy completedNCT00002924
What this trial is testing

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Who this might be right for
Prostate Cancer
Alliance for Clinical Trials in Oncology 184
Testing effectiveness (Phase 2)Study completedNCT00061126
What this trial is testing

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

Who this might be right for
Prostate Cancer
Abgenix 50
Large-scale testing (Phase 3)Study completedNCT00364455
What this trial is testing

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Who this might be right for
ProstateCarcinoma
Janssen-Ortho Inc., Canada 56
Testing effectiveness (Phase 2)Study completedNCT00216099
What this trial is testing

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Christopher Sweeney, MBBS 49
Large-scale testing (Phase 3)Study completedNCT01254279
What this trial is testing

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Who this might be right for
Prostate Cancer Metastatic
Sanofi 984
Early research (Phase 1)Ended earlyNCT01510288
What this trial is testing

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Amsterdam UMC, location VUmc 28
Testing effectiveness (Phase 2)Study completedNCT00183924
What this trial is testing

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

Who this might be right for
Prostate Adenocarcinoma
University of Southern California 20
Testing effectiveness (Phase 2)Study completedNCT00407251
What this trial is testing

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

Who this might be right for
Hormone Refractory Prostate Cancer
British Columbia Cancer Agency 73
Large-scale testing (Phase 3)Study completedNCT00699751
What this trial is testing

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Who this might be right for
Hormone Refractory Prostate CancerBone Metastases
Bayer 921
Next Page